VanEck JP Morgan EM Local Currency Bond ETF vs Gilead Sciences, Inc. — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.6, while Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | GILD | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $155.80 |
52-Week Low | $24.83 | $110.56 |
Market Cap | — | $168.35B |
Enterprise Value | — | $191.42B |
Dividend Yield | — | 2.42% |
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.59, down 0.12% on the day, with a bullish technical signal driven by moving averages. Recent dividends include H2-26 payments of $0.13 and $0.14, indicating income focus. Support and resistance cluster at $26, suggesting consolidation near this level.
Outlook remains cautious due to missing fundamental data; risks include emerging market volatility and Fed policy sensitivity. Opportunities hinge on yield appeal if U.S. rates decline, but investor sentiment is mixed amid macroeconomic uncertainties.
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Trailing returns across standard periods
Latest headlines on both assets
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →